Literature DB >> 11832443

Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis.

Linda M Fletcher1, Jeannette L Dixon, David M Purdie, Lawrie W Powell, Darrell H G Crawford.   

Abstract

BACKGROUND & AIMS: The progression of fibrosis to cirrhosis is the most significant prognostic factor in hereditary hemochromatosis. We aimed to determine the range of hepatic iron concentration associated with cirrhosis in the absence of alcohol and other pro-fibrogenic cofactors and to quantify the contribution of excess alcohol consumption to the development of cirrhosis.
METHODS: Liver biopsy data were evaluated on 224 C282Y homozygous hemochromatosis subjects. To determine the effect of alcohol alone on the development of fibrosis, subjects with viral hepatitis or nonalcoholic steatohepatitis were excluded. Subjects were divided into those who consumed less than 60 g alcohol per day and those who consumed 60 g per day or more.
RESULTS: Seven percent of subjects who consumed less than 60 g per day had severe fibrosis/cirrhosis compared with 61% of excess alcohol consumers.
CONCLUSIONS: Hemochromatosis subjects who drink more than 60 g alcohol per day are approximately 9 times more likely to develop cirrhosis than those who drink less than this amount, and the range of hepatic iron concentration associated with cirrhosis in the absence of cofactors was 233-675 micromol/g dry weight.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832443     DOI: 10.1053/gast.2002.30992

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

Review 1.  Phenotypic expression of hereditary hemochromatosis: what have we learned from the population studies?

Authors:  Eng K Gan; Oyekoya T Ayonrinde; Debbie Trinder; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2010-02

2.  Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan.

Authors:  Haris Riaz; Talha Riaz; Muhammad Ubaid Khan; Sina Aziz; Faizan Ullah; Anis Rehman; Qandeel Zafar; Abdul Nafey Kazi
Journal:  BMC Res Notes       Date:  2011-08-11

Review 3.  A diagnostic approach to hemochromatosis.

Authors:  Anthony S Tavill; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

4.  Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy.

Authors:  A W Demant; A Schmiedel; R Büttner; T Lewalter; C Reichel
Journal:  Clin Res Cardiol       Date:  2007-08-20       Impact factor: 5.460

5.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

6.  Transforming growth factor-β and toll-like receptor-4 polymorphisms are not associated with fibrosis in haemochromatosis.

Authors:  Marnie J Wood; Lawrie W Powell; Jeannette L Dixon; V Nathan Subramaniam; Grant A Ramm
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

7.  HFE genetic variability and risk of alcoholic liver disease: A meta-analysis.

Authors:  Yan-Yan Xu; Yu-Han Tang; Xiao-Ping Guo; Jing Wang; Ping Yao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

8.  Clinical penetrance of C282Y homozygous HFE haemochromatosis.

Authors:  Enrico Rossi; Gary P Jeffrey
Journal:  Clin Biochem Rev       Date:  2004-08

Review 9.  Management of alcohol misuse in patients with liver diseases.

Authors:  Jennifer L Peng; Milan Prakash Patel; Breann McGee; Tiebing Liang; Kristina Chandler; Sucharat Tayarachakul; Sean O'Connor; Suthat Liangpunsakul
Journal:  J Investig Med       Date:  2016-12-09       Impact factor: 2.895

10.  HFE-Related Hemochromatosis: The Haptoglobin 2-2 Type Has a Significant but Limited Influence on Phenotypic Expression of the Predominant p.C282Y Homozygous Genotype.

Authors:  Gérald Le Gac; Chandran Ka; Isabelle Gourlaouen; Laurence Bryckaert; Anne-Yvonne Mercier; Brigitte Chanu; Virginie Scotet; Claude Férec
Journal:  Adv Hematol       Date:  2009-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.